Patents matching “ONC”

US 2020030466

Stable, concentrated radionuclide complex solutions

ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Jan 30, 2020 · Expires Jan 25, 2040

US 2020030465

Stable, concentrated radionuclide complex solutions

ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Jan 30, 2020 · Expires Jan 25, 2040

US 10525051

Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Nektar Therapeutics · Granted Jan 7, 2020 · Expires Jan 2, 2040

US 10471055

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

US 10426767

Methods of treating cancer with farnesyltransferase inhibitors

Kura Oncolofy, Inc. · Granted Oct 1, 2019 · Expires Sep 26, 2039

US 10421813

Oncostatin M receptor antigen binding proteins

Kiniksa Pharmaceuticals, GmbH · Granted Sep 24, 2019 · Expires Sep 19, 2039

US 10377772

Macrocyclic LRRK2 kinase inhibitors

Oncodesign SA · Granted Aug 13, 2019 · Expires Aug 8, 2039

US 10357553

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology · Granted Jul 23, 2019 · Expires Jul 18, 2039

US 10344033

2-aminoquinazoline derivatives as P70S6 kinase inhibitors

SENTINEL ONCOLOGY LIMITED · Granted Jul 9, 2019 · Expires Jul 4, 2039

US 10335404

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Jul 2, 2019 · Expires Jun 27, 2039

US 10301317

Inhibitors of ERK and methods of use

Kura Oncology, Inc. · Granted May 28, 2019 · Expires May 23, 2039

US 10292979

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted May 21, 2019 · Expires May 16, 2039

US 10260101

C-kit oncogene mutations in melanoma

The Regents of the University of California · Granted Apr 16, 2019 · Expires Apr 11, 2039

US 10239949

Oncofetal antigen binding proteins and related compositions and methods

Aptevo Research and Development LLC · Granted Mar 26, 2019 · Expires Mar 21, 2039

US 10238698

Biomarkers and combination therapies using oncolytic virus and immunomodulation

The Board of Regents of the University of Texas System · Granted Mar 26, 2019 · Expires Mar 21, 2039

US 10195214

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated · Granted Feb 5, 2019 · Expires Jan 31, 2039

US 10167452

Viral purification methods

ONCOLYTICS BIOTECH INC. · Granted Jan 1, 2019 · Expires Dec 27, 2038

US 10159727

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology · Granted Dec 25, 2018 · Expires Dec 20, 2038

US 10144726

Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer

SENTINEL ONCOLOGY LIMITED · Granted Dec 4, 2018 · Expires Nov 29, 2038

US 10137121

Methods of treating cancer with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Nov 27, 2018 · Expires Nov 22, 2038

US 10130607

Methods of reducing blood lactate concentration

Stokely-Van Camp, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

US 10105344

Methods of reducing blood lactate concentration

Stokely-Van Camp, Inc. · Granted Oct 23, 2018 · Expires Oct 18, 2038

US 10080774

Oncolytic adenovirus armed with therapeutic genes

The Board of Regents of the University of Texas System · Granted Sep 25, 2018 · Expires Sep 20, 2038

US 10047401

Expression protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 14, 2018 · Expires Aug 9, 2038